touchPODCAST

touchMDT for touchCARDIO

Listen to key experts from a multidisciplinary team consider the unmet needs in patients at high risk of ASCVD and how novel lipid-lowering therapies may help 

The multidisciplinary team

• Endocrinologist: Professor Lawrence Leiter, Canada

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.

For further information visit our website: https://touchcardioime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk//

touchMDT for touchCARDIO

Listen to key experts from a multidisciplinary team discuss the risk factors and lipoproteins associated with ASCVD and guideline recommendations for the management of patients with dyslipidemia.

The multidisciplinary team

• Cardiologist: Dr Constantine Kosmas, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novartis Pharma AG, Basel, Switzerland. This medical education is provided by touchIME.

For further information visit our website: https://touchcardioime.org/novel-lipid-lowering-therapies-for-reducing-ascvd-risk//

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts in breast cancer share their opinion on the latest data which may help guide the use of CDK4/6 inhibitors in HR+/HER2- advanced breast cancer.

The experts

• Dr Luca Malorni - Hospital of Prato, Italy

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novartis and is provided by touchIME. 

For further information visit our website: https://touchoncology.com/education/cdk-inhibitors-breast-cancer/

touchPANEL DISCUSSION for touchIMMUNOLOGY

Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.

The experts

• Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.

For further information visit our website: https://touchimmunologyime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/

touchPANEL DISCUSSION for touchRESPIRATORY

Listen to a panel of experts discuss using biologics to optimize outcomes for patients with type 2 asthma and how biomarkers can inform treatment decisions.

The experts

• Dr Michael Wechsler - National Jewish Health and University of Colorado, Denver, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This activity is provided by touchIME.

For further information visit our website: https://touchrespiratoryime.org/pd-in-disease-control-in-moderate-to-severe-type-2-asthma/

touchCONGRESS for touchIMMUNOLOGY

Walter Maksymowych (University of Alberta, Alberta, Canada) talks to touchIMMUNOLOGY about the results of the C-axSpAnd Study (NCT02552212). This 52-week placebo-controlled study aimed to identify demographic or baseline characteristics of patients with nr-axSpA that could be predictive of achieving a clinical response to treatment with certolizumab pegol.

The abstract entitled ‘Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study’ was presented at ACR Convergence 2020, 5-9 November.

touchEXPERT OPINIONS for touchONCOLOGY

Listen to leading experts discuss how monoclonal antibody (MAb) biosimilars for solid tumours are developed and approved, and learn about the practical aspects of their use in oncology pharmacy.

The experts

• Dr Paul Cornes - Comparative Outcomes Group, Bristol, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical educational grant from Pfizer. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/mab-biosimilars-in-the-treatment-of-solid-tumours-perspectives-for-pharmacists/

touchCONGRESS for touchONCOLOGY

Listen to key highlights from SABCS Virtual 2020.  This touchPODCAST is presented by Prof. Dr Nadia Harbeck.  

We specifically focus on data presented at this congress describing CDK4/6 inhibitors in HR+/HER2- breast cancer and what these data could mean for clinical practice. 

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from Eli Lilly.  This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/hrher2-breastcancersabcs2020touchcongress/

touchCONGRESS for touchONCOLOGY

Listen to key highlights from ESMO Virtual 2020. This touchPODCAST is presented by Dr Catherine Kelly. 

We specifically focus on data presented at this congress describing CDK4/6 inhibitors in HR+/HER2- breast cancer and what these data could mean for clinical practice. 

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical educational grant from Eli Lilly. This activity is provided by touchIME.

For further information visit our website: https://touchoncologyime.org/hrher2-breastcanceresmo2020touchcongress/